Free Stock Tips

Hi Everybody,

According to the American Cancer Society approximately 1.5 million new cases of cancer are diagnosed each year in the U.S. Today, there are over 11 million Americans living with cancer.

Our alert for Monday is in the development process of a patented anti-cancer compound.

Our alert for Monday is:
Sunshine Biopharma, Inc.
Ticker symbol: SBFM
Last price: 10 cents

SBFM is a pharmaceutical company that researches, develops and commercialises drugs for the treatment of various forms of cancer,

Adva-27a is SBFM’s patented lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells.

The early stage preclinical studies for SBFM’s lead compound, Adva-27a, were successfully completed.

SBFM is planning a phase 1 clinical trial of Adva-27a for pancreatic cancer in parallel to the phase 1 clinical trial of Adva-27a for multidrug resistant breast cancer.

Recently, SBFM has been making the necessary steps to get to trials.

SBFM is currently negotiating with several contract research organizations (CRO’s) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a. A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process.

SBFM is also preparing to sell generic pharmaceuticals in an effort to produce revenues that should help fund the costly process associated with clinical trials.

SBFM has secured dedicated space in order to commence operations in the generic pharmaceuticals business as planned. Having a specifically dedicated space is required in order for the company to be granted a Pharmaceutical Establishment and Export License by Health Canada.

Once secured the establishment license will allow SBFM to sign manufacturing and distribution contracts for sale of generic pharmaceuticals in Canada and elsewhere around the globe.

As SBFM gets closer to clinical trials the stock could really heat up.

If you aren’t familiar with the clinical trial process, each stage when successfully completed is usually the catalyst for a large move for the stock.

SBFM is receiving a ton of awareness this week and we think traders and investors alike will benefit from buyers coming in ahead of phase 1.

Get ready to book your profits with SBFM.

As always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading